Why Collaboration in Pharmaceutical Logistics Matters More Than Ever

The pharmaceutical supply chain has always relied on a certain amount of interdependence. From collaborative research to co-ordination of multi-leg deliveries, the secure movement of sensitive medicines relies on a network of organisations working together under intense regulatory and operational pressure.

LogiPharma 2026

And, whilst geopolitical conditions have always added to those pressures, the last few years have stretched the industry further than ever before. The addition of tariff wars to broader regional conflict, steadily increasing climate-related incidents, the growing but uncertain role of AI and how it is adopted around the world — all of these factors have shaped a landscape which makes collaboration a strategic necessity.

For pharmaceutical stakeholders, the challenge now goes beyond protecting product in transit, it’s about continuity of care in the face of repeated, hard-to-predict disruption.

Cold Chain Collaboration

Cold chain logistics arguably represents the frontline of this challenge. The high value, high sensitivity, sometimes clinically critical, nature of the products transported via the cold chain means that any form of disruption can result in major consequences; financial, regulatory, and most importantly patient-related.

The security of the cold chain has been massively enhanced by the widespread adoption of real-time tracking, but visibility alone is not enough to navigate the various sources of disruption facing shipments today. While visibility in isolation provides a foundational level of resilience, data sharing, common standards and intelligent modelling offer a more robust approach to cold chain security.

LogiPharma 2026

Increasingly, cold chain specialists are collaborating from the early phases of shipment planning. For example, the packaging provider may now liaise with the data modelling partner to add predictive insights into the process of determining the most appropriate packaging for a sensitive shipment. Or a manufacturer collaborating with its cold chain logistics partner may develop a downstream communications process that enables pharmacies to better track and plan around deliveries.

This integration of multiple cold chain supply and logistics stakeholders can be cross-organisational or cross-functional, depending on whether a manufacturer chooses multiple providers or one end-to-end service. But the communication of information throughout the supply chain, and the sharing of best practice, is becoming crucial to the successful evolution of the pharmaceutical sector as a whole, especially when it comes to emerging technology.

AI Adoption

Artificial intelligence has become increasingly central to industry discussion in the last few years, especially as technology has accelerated over the last 18 months.

The potential for AI within pharmaceutical supply chains is vast. It can support forecasting, inventory positioning, route assessment, anomaly detection and decision triage. For cold chain logistics in particular, AI-powered data management can analyse shipment data, monitor thermal behaviour, identify route performance issues and support proactive modelling before shipments take place.

Effectively, AI can be harnessed to shift the entire objective of pharmaceutical logistics from shipment protection to optimisation. However, in order for it’s potential to be realised, it is vital that pharmaceutical stakeholders communicate and unite on how it is used and how it is regulated.

The EU AI Act, for example, which classifies pharma as a ‘high risk’ application comes into force on 6 August this year. And, while mostly regarded as applicable to medical devices, will also impact pharma logistics. AI driven temperature-control units, systems used for critical distribution, and the data governance of information collected for traceability purposes are all likely affected by the Act, and stakeholders throughout the supply chain will need to collaborate to ensure end-to-end compliance.

The human management of AI is also reliant on collaboration. While AI is able to augment decision-making through better visibility and expedited data interpretation, accountability cannot be wholly delegated to algorithms.

Whilst AI can help detect and report a delayed shipment, temperature excursion or an inventory shortage, the response requires human experience, judgement, and crucially, communication. Once an issue is detected, developing a response often relies on engagement and information sharing from different areas of the supply chain, across commercial relationships and functions. Ultimately, successful human-in-the-loop means effective communication between multiple humans operating in their own AI loops, creating a network of co-operation which optimises how the technology is used.

Building Sustainability

Sustainability is another area in which industry-wide collaboration is required for progression.

While the pharmaceutical sector has made great strides in reducing operational emissions, Scope 3 supply chain emissions remain one of its most difficult challenges.

Complete decarbonisation may feel like an unrealistic goal today, but gradually improving the carbon footprint of a supply chain is certainly possible, and achievable by the collaboration of stakeholders across the industry.

No single organisation has the ability to decarbonise an end-to-end pharmaceutical supply chain in isolation, but with co-ordinated participation, initiatives such as reusable packaging and reverse logistics, supplier emissions tracking, and lower-carbon transport are made possible.

Reusable temperature-controlled packaging, for example, can reduce waste, but only if the system around it supports return, cleaning, tracking, redeployment and clear allocation of responsibility. Similarly, reverse logistics, for expired, damaged, returned or recalled products presents the opportunity for sustainability gains, but only through collaboration which navigates strict national and international regulations.

Raising the bar for sustainability relies on individual elements of the supply chain coming together to ensure the success of often hard-to-implement ways of working. For manufacturers reliant on supply chain providers to help them deliver against ESG targets, that element of inter-discipline support is highly valuable.

Creating Global Health Equity

Pharmaceutical supply chains do not exist only to optimise cost or efficiency; their fundamental purpose is to ensure that patients can access medicines and treatments when they need them.

That purpose becomes especially urgent when considering vaccine access, pandemic preparedness and healthcare delivery in remote or vulnerable regions. Conflict, tariffs, and reduced aid spend translate to real jeopardy when it comes to equitable access to medication, and industry partnerships are critical for supporting distribution amidst these challenges.

Partnerships between pharmaceutical companies, NGOs, non-profits, logistics providers and public health organisations have an important role to play in addressing inequity. However, the way these partnerships are structured and what they deliver is not set. Practical and ethical considerations can vary across projects, and this lack of alignment can result in delays which impact patients.

LogiPharma 2026

This is where industry forums can play a meaningful role. Events like LogiPharma facilitate peer discussion and information sharing which provides the conditions for difficult questions to be explored collectively. In terms of furthering the interests of the industry as a whole and greatening the impact that pharma can have on the wellbeing of patients worldwide, the power of open conversation cannot be underestimated.

Conclusion

The need for stronger collaboration is being sharpened by the wider geopolitical climate. Tariffs, trade wars and regional conflict are creating supply chain risks across global pharmaceutical networks, while the balance between globalisation, nearshoring and reshoring continues to shift.

These tensions cannot be solved by any single organisation acting alone. A culture of collaboration and information sharing is central to the implementation of practices which benefit the industry and allow businesses across the supply chain to not only survive disruption, but to thrive in the face of challenge.

By continuing to collectively discuss the obstacles facing pharmaceutical stakeholders, both at global forum level and in small scale peer-to-peer interactions, we can build a supply chain which benefits everyone.

Ben Sharples at LogiPharma 2026

About the Author: Ben Sharples

Ben Sharples is a seasoned professional with extensive experience in event management and business strategy. Currently serving as event director for LogiPharma, Ben aims to facilitate industry-critical conversations for pharmaceutical professionals globally.